Versus Everolimus News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Versus everolimus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Versus Everolimus Today - Breaking & Trending Today

FDA Approves Belzutifan for Treatment of Advanced Renal Cell Carcinoma

Belzutifan (Welireg; Merck) demonstrated superior progression-free survival compared to everolimus in advanced renal cell carcinoma. ....

Tonik Choueiri , Merck Research Laboratories , Merck Sharp Dohme , Lank Center , Genitourinary Oncology At Dana Farber Cancer Institute , Genitourinary Oncology , Dana Farber Cancer Institute , Versus Everolimus , Participants With Advanced Renal Cell Carcinoma , Merck Sharp , Completion Date ,

ASCO GU 2021: Best of Journals: Renal Cell Carcinoma – Medical Oncology

Published 14 February 2021
(UroToday.com) The 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium included a Best of Journals: Renal Cell Carcinoma Session with Dr. Saby George from the Roswell Park Cancer Institute presenting impactful papers from the medical oncology perspective.
The first paper discussed by Dr. George was Motzer et al. s “Nivolumab Versus Everolimus in Patients with Advanced Renal Cell Carcinoma: Updated Results with Long-Term Follow-Up of the Randomized, Open-Label, Phase 3 CheckMate 025 Trial” was published in
Cancer.
1 CheckMate 025 previously showed superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma along with improved safety and tolerability. ....

New York , United States , Roswell Park , Habib Hamidi , Zachary Klaassen , David Mcdermott , Saby George , Scotts Tykodi , Bernard Escudier , Jeffreya Sosman , Romain Banchereau , Thomas Powles , Michaelb Atkins , American Society Of Clinical Oncology , Georgia Cancer Center , Roswell Park Cancer Institute , Augusta University Medical College Of Georgia , Clinical Oncology , Cancers Symposium , Renal Cell Carcinoma Session , Versus Everolimus , Advanced Renal Cell Carcinoma , Updated Results , Long Term Follow Up , Renal Cancer Determine Outcome , Associate Professor ,